article thumbnail

Pfizer Responds to Research Claims

Pfizer

This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.

Research 112
article thumbnail

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. Institute hormone replacement therapy for endocrinopathies as warranted. Administer hormone-replacement therapy for hypothyroidism. Immune-Mediated Pneumonitis.

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. Institute hormone replacement therapy for endocrinopathies as warranted. Administer hormone-replacement therapy for hypothyroidism. Immune-Mediated Pneumonitis.

Trials 52
article thumbnail

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

The Pharma Data

The BTK protein sends important signals that tell B cells to mature and produce antibodies. Advise nursing women to discontinue breastfeeding during treatment. Isolated growth hormone deficiency. ? BTK signaling is needed by specific cancer cells to multiply and spread. This is not a complete summary of all safety information.

article thumbnail

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

The Pharma Data

The BTK protein sends important signals that tell B cells to mature and produce antibodies. Advise nursing women to discontinue breastfeeding during treatment. Isolated growth hormone deficiency. ? BTK signaling is needed by specific cancer cells to multiply and spread. This is not a complete summary of all safety information.